SEC Info - Humacyte, Inc. - ‘8-K’ for 2/9/24

SEC Info℠

Home

Help

Please Sign In

Humacyte, Inc. – ‘8-K’ for 2/9/24

On: Friday, 2/9/24, at 8:06am ET · For: 2/9/24 · Accession #: 1818382-24-5 · File #: 1-39532

  As Of               Filer                 Filing    For·On·As Docs:Size

 2/09/24  Humacyte, Inc.                    8-K:8,9     2/09/24   12:242K

Current Report — Form 8-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     29K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML     17K 
 7: R1          Cover Page                                          HTML     52K 
 9: XML         IDEA XML File -- Filing Summary                      XML     12K 
12: XML         XBRL Instance -- huma-20240209_htm                   XML     18K 
 8: EXCEL       IDEA Workbook of Financial Report Info              XLSX      8K 
 4: EX-101.DEF  XBRL Definitions -- huma-20240209_def                XML     41K 
 5: EX-101.LAB  XBRL Labels -- huma-20240209_lab                     XML     85K 
 6: EX-101.PRE  XBRL Presentations -- huma-20240209_pre              XML     42K 
 3: EX-101.SCH  XBRL Schema -- huma-20240209                         XSD     11K 
10: JSON        XBRL Instance as JSON Data -- MetaLinks               14±    20K 
11: ZIP         XBRL Zipped Folder -- 0001818382-24-000005-xbrl      Zip     24K

‘8-K’ — Current Report

This is an HTML Document rendered as filed. [ Alternative Formats ]

iX:

huma-20240209

i 0001818382 i FALSE00018183822024-02-092024-02-090001818382us-gaap:CommonStockMember2024-02-092024-02-090001818382us-gaap:WarrantMember2024-02-092024-02-09

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM i 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): i February 9, 2024

i i Humacyte, Inc. /

(Exact name of registrant as specified in its charter)


i Delaware	i 001-39532	i 85-1763759
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S. Employer Identification Number)


i 2525 East North Carolina Highway 54
i Durham,	i NC	i 27713
(Address of principal executive offices)		(Zip code)

( i 919) i 313-9633

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


i o			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
i o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
i o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
i o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which
registered

i Common Stock, par value $0.0001 per share

i HUMA

i The Nasdaq Stock Market LLC

i Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50

i HUMAW

i The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company i x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. i o

Item 8.01. Other Events.

On February 9, 2024, Humacyte, Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration has accepted and granted Priority Review to the Company’s Biologics License Application seeking approval of the Company’s human acellular vessel in urgent arterial repair following extremity vascular trauma when a synthetic graft is not indicated and when autologous vein use is not feasible. A copy of this press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.


Exhibit Number						Description
99.1						Press release, dated February 9, 2024.

104						Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	HUMACYTE, INC.

Date: February 9, 2024	By:	/s/ *Dale A. Sander*
		Name:	Dale A. Sander
		Title:	Chief Financial Officer, Chief Corporate Development Officer and Treasurer

Dates Referenced Herein and Documents Incorporated by Reference

This ‘8-K’ Filing	Date	Other Filings

Filed on / For Period end:	2/9/24	None on these Dates
		List all Filings

3 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/28/24  Humacyte, Inc.                    S-8         3/28/24    4:101K
 3/01/24  Humacyte, Inc.                    424B5                  1:540K
 2/29/24  Humacyte, Inc.                    424B5                  1:536K

↑Top

Filing Submission 0001818382-24-000005 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)